Cure My Disease

Don't miss your cure!

 Log in / Sign up

New combo therapy aimed at Hard-to-Treat liver disease

NCT ID NCT04594694

Terminated Disease control Sponsor: Intercept Pharmaceuticals Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jul 17, 2026 · Updated 2 times

Summary

This study tested whether combining two drugs, obeticholic acid and bezafibrate, could improve liver health in people with primary biliary cholangitis (PBC) who did not respond well to or could not take the standard medicine. The trial enrolled 75 adults and measured changes in a key liver enzyme over 12 weeks. The study was terminated early, so results are limited.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PRIMARY BILIARY CHOLANGITIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Fibrosis primary biliary cholangitis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PRIMARY BILIARY CHOLANGITIS

Contacts and locations

Locations

  • Academisch Medisch Centrum

    Amsterdam, 1105 AZ, Netherlands

  • Artroscan s.r.o., Gastroenterologicka ambulance

    Ostrava, 722 00, Czechia

  • Budai Hepatologiai Centrum (BHC)

    Budapest, 1111, Hungary

  • CHRU de Lille

    Lille, 59000, France

  • CHU Paris Est - Hopital Saint Antoine

    Paris, Paris 12, France

  • Centre Hospitalier Universitaire Grenoble

    Grenoble, 38043, France

  • Clinical Hospital Dubrava

    Zagreb, 10000, Croatia

  • Consorcio Hospital General Universitario

    Valencia, 46010, Spain

  • DEOEC II. sz. Belgyógyászati Klinika

    Debrecen, 4032, Hungary

  • Department of Medicine and Research Laboratory of Internal Medicine, University Hospital of Larissa

    Larissa, 41110, Greece

  • Flinders Medical Centre

    Bedford Park, Perth, 5042, Australia

  • Fundacio Clinic Per La Recerca Biomedica

    Barcelona, 08036, Spain

  • Groupe Hospitalier Pitié Salpêtrière - Assistance publique - Hôpitaux de Paris

    Paris, 75651, France

  • Hadassah Ein-Karem Medical Center - Liver unit

    Jerusalem, 91120, Israel

  • Hepato-Gastroenterologie HK, s.r.o.

    Hradec Králové, 500 12, Czechia

  • Hospital of Lithuanian University of Health Sciences, Kauno Klinikos

    Kaunas, 50161, Lithuania

  • Hull University Teaching Hospitals NHS Trust

    Hull, HU3 2JZ, United Kingdom

  • Hôpital Henri Mondor

    Créteil, 940000, France

  • Institute of Cellular Medicine, Newcastle University

    Newcastle upon Tyne, NE2 4HH, United Kingdom

  • John Radcliffe Hospital

    Oxford, OX3 9DU, United Kingdom

  • Kyungpook National University Hospital

    Daegu, 41944, South Korea

  • Medizinische Hochschule Hannover

    Hanover, 30625, Germany

  • Narodowy Instytut Onkologii, Klinika Gastroenterologii Onkologicznej

    Warsaw, 02-781, Poland

  • Pusan National University Hospital

    Busan, 602-739, South Korea

  • Research Site s.r.o.

    Pilsen, 301 00, Czechia

  • Royal Adelaide Hospital

    Adelaide, 5000, Australia

  • Tartu University Hospital

    Tartu, 51014, Estonia

  • Tel Aviv Surasky Medical Center

    Tel Aviv, 6423906, Israel

  • UZ Gasthuisberg

    Leuven, 3000, Belgium

  • Universitatsklinikum Hamburg-Eppendorf UKE

    Hamburg, 20246, Germany

  • Universitetet i Oslo - Akershus Universitetssykehus (AHUS)

    Loerenskog, 1478, Norway

  • Vlinius University

    Vilnius, 08661, Lithuania

  • Zagreb University Hospital Center

    Zagreb, 10000, Croatia

More trials for these conditions

Other studies related to the condition(s) this trial covers.